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Abstract
Background: Among the epigenetic alterations occurring in cancer, DNA hypermethylation and
histone hypoacetylation are the focus of intense research because their pharmacological inhibition
has shown to produce antineoplastic activity in a variety of experimental models. The objective of
this study was to evaluate the combined antineoplastic effect of the DNA methylation inhibitor
hydralazine and the histone deacetylase inhibitor valproic acid in a panel of cancer cell lines.
Results: Hydralazine showed no growth inhibitory effect on cervical, colon, breast, sarcoma,
glioma, and head & neck cancer cell lines when used alone. On the contrary, valproic acid showed
a strong growth inhibitory effect that is potentiated by hydralazine in some cell lines. Individually,
hydralazine and valproic acid displayed distinctive effects upon global gene over-expression but the
number of genes over-expressed increased when cells were treated with the combination.
Treatment of HeLa cells with hydralazine and valproic acid lead to an increase in the cytotoxicity
of gemcitabine, cisplatin and adriamycin. A higher antitumor effect of adriamycin was observed in
mice xenografted with human fibrosarcoma cells when the animals were co-treated with
hydralazine and valproic acid.
Conclusion:  Hydralazine and valproic acid, two widely used drugs for cardiovascular and
neurological conditions respectively have promising antineoplastic effects when used concurrently
and may increase the antitumor efficacy of current cytotoxic agents.
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Background
Modulation in the expression of cancer-related genes
silenced by changes in DNA methylation and histone
post-translational modification through the use of DNA
methylation and histone deacetylase inhibitors has been
shown to exert antitumor effects in in vitro and in vivo
models [1]. These results have led to the development of
these class of drugs for clinical use. The classical demeth-
ylating agents comprise analogs of deoxycytidine: 5-aza-
cytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuranosil-
5-azacytosine, and dihydro-5-azacytidine, developed over
the past 30 years as classical cytotoxic agents, and subse-
quently discovered as DNA methylation inhibitors [2].
Another class of demethylating agent is the antisense oli-
gonucleotide MG98 directed against the3' untranslated
region of DNMT1 mRNA, which codes for the enzyme
DNA methyltransferase 1 responsible for maintenance of
DNA methylation [3]. The fact that deoxycytidine analogs
such as 5-aza-2-deoxycytidine are not only carcinogenic
but also exhibit neutropenia as their dose-limiting toxicity
when used for demethylation [4] has renewed interest in
finding effective and less toxic demethylating agents.
Among these are an oral cytidine analog zebularine [5]
and the green tea major polyphenol (-)-epigallocatechin-
3-gallate [6]. Our group has recently shown in vitro and in
vivo promoter demethylation and tumor suppressor gene
transcriptional reactivation mediated by the antihyperten-
sive compound hydralazine, a well-tolerated drug devoid
of the common side effects of cytotoxic chemotherapy
agents [7] and whose DNA demethylating activity can be
explained by the interaction between its nitrogen atoms
with residues Lys162 and Arg240 of the DNA methyl-
transferase active site, as shown in a silico model [8]. Its
demethylating and gene reactivating activity were also
shown in a phase I trial [9].
On the other hand, HDAC inhibition has been reported
to induce tumor cell differentiation, apoptosis, or growth
arrest, depending on the experimental system [10,11],
and to sensitize cells to chemotherapy [12] or radiation
therapy [13]. Currently, there are six structurally distinct
classes of HDAC inhibitors at diverse stages of preclinical
and clinical development. Valproic acid, an 8-carbon,
branched-chained fatty acid well-known as an effective
antiepileptic drug [14] belongs to the Small molecular
weight carboxilates [15]. This drug causes hyperacetylation
of the N-terminal tails of histones H3 and H4 in vitro and
in vivo and inhibits HDAC activity, most probably by
binding to the catalytic center and thereby blocking sub-
strate access [16,17]. In contrast to other HDAC inhibi-
tors, valproic acid has a good tolerability and safety profile
as demonstrated by 35 years of use as a chronic therapy for
epileptic disorders [14]. Its ability to inhibit deacetylase
activity in solid tumors has recently been demonstrated
In vitro growth inhibition by hydralazine, valproic acid and  the combined treatment Figure 1
In vitro growth inhibition by hydralazine, valproic 
acid and the combined treatment. Hydralazine had not 
growth inhibitory effects at the dose and conditions tested in 
none of the cell lines. Valproic acid induced a variable degree 
of inhibition in the cell lines. D54 glioma cell line had 80% 
growth inhibition whereas KB laryngeal carcinoma was the 
least but still inhibition was close to 50%. MCF-7 and SW480 
were more sensitive to the combination of compounds 
although the difference was statistically significant only in 
SW480 cells (p < 0.001)Cancer Cell International 2006, 6:2 http://www.cancerci.com/content/6/1/2
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[18]. We thus investigated if the use of both compounds
in combination displayed an increased antineoplastic
effect.
Results
Inhibitory activity of hydralazine and valproic acid in vitro
Cells lines from different tumor types were treated with
either hydralazine, valproic acid or the combination at 10
µM and 1 mM respectively for five days. As shown in Fig-
ure 1 all cell types were statistically significant growth
inhibited to various degrees by valproic acid. D54 glioma
cell line had 80% growth inhibition whereas KB laryngeal
carcinoma was the least but still inhibition was close to
50%. On the other hand, hydralazine had no growth
inhibitory effect at the dose and conditions tested. When
used in combination, five of the seven cell lines showed
the same inhibition that valproic acid alone. Interestingly,
MCF-7 and SW480 were more sensitive to the combina-
tion of compounds although the difference was statisti-
cally significant only in SW480 cells (p < 0.001).
Gene expression
To analyze any change in the global pattern of gene
expression induced by these epigenetic active drugs,
genome wide expression analysis was performed follow-
ing drug treatment as described in methods section. RNA
purified from SW480 was hybridized on the CodeLink
system (Amersham; Piscataway, NJ). This array contains a
broad range of genes derived from publicly available,
well-annotated mRNA sequences (over 55,000 genes and
ESTs probes). Following normalization and log2 transfor-
mation, data were loaded on Cluster 3.0; Log 2 expression
ratios were filtered to find genes with a minimum expres-
sion ratio of three-fold different from untreated controls.
Hence we obtained 1281 differentially expressed genes
(651 up-regulated and 630 down-regulated, supplemen-
tary information). Hierarchical clustering revealed specific
patterns induced by each treatment (Figure 2). In this
method of clustering, relationships among objects
(genes)are represented by a tree whose branch lengths
reflect the degree of similarity between the objects, as
assessed by a pairwise similarity function. The computed
trees can be used to order genes in the original data table,
so that genes or groups of genes with similar expression
patterns are adjacent. The ordered table can then be dis-
played graphically as figure 2, with a representation of the
tree to indicate the relationships among genes. Interest-
ingly, most down-regulated genes were co-regulated by
either drug, alone or combined. On the contrary, up-regu-
lated genes were somehow specific for each treatment. It
was found that 153, 178 and 352 genes were specifically
induced 3-fold by hydralazine, valproic acid or the com-
bined treatment respectively. Additional files 1, 2 and 3
list the genes with the highest degree of over-expression
that also have a function known. The complete list of
genes whose expression changed is provided as supple-
mentary information (additional file 4).
Effect of cytotoxic drugs in combination with hydralazine 
and valproic acid in HeLa cells
HeLa cells were treated for 24 hours with cisplatin, adri-
amycin or gemcitabine at or close to IC50 plus hydralazine
and valproic acid. Afterwards medium was removed and
fresh medium containing only hydralazine and valproic
acid was added for additional 48 hours after which viabil-
ity was measured. Figure 3 shows a statistically significant
higher cytotoxicity of the chemotherapeutic agent when
used in combination with hydralazine plus valproic acid.
Cisplatin alone at 12 µM caused a reduction in viability to
37% in HeLa cells which was essentially zero viability
when cells were co-treated with hydralazine plus valproic
acid (p < 0.002). The increasing toxicity of the combina-
tion was also seen with adriamycin and gemcitabine. Via-
bility was 42% and 45% in the chemotherapy drugs alone
versus 27% (p < 0.020) and 37% (p < 0.012) respectively,
when hydralazine plus valproic acid were added.
Antitumor evaluation of the combination in vivo
To investigate whether the hydralazine and valproic acid
combination has antitumor effects in vivo, we used a sar-
coma xenograft model in nu/nu mice. Animals were
treated with adriamycin by the intraperitoneal route with
a dose of 2.2 mg/Kg on a weekly basis for 3 weeks, starting
when the tumor volume reached at least 1 cm in its larger
diameter. Treatment with hydralazine plus valproic acid
started the week (day 1) before the first injection of adri-
amycin (day 7) and continued until animals were sacri-
ficed. Figure 4 shows that in untreated control animals
tumor growth increased rapidly whereas in the animals
treated with adriamycin with or without hydralazine plus
valproic acid, tumors disappeared at day 21. However,
there was a rapid regrowth starting at day 21 in the ani-
mals treated only with adriamycin, whereas animals
treated with hydralazine plus valproic acid remained free
of tumor.
Discussion
Aberrant gene transcription resulting from epigenetic
changes, -namely DNA promoter hypermethylation and
histone deacetylation- are frequent events in the molecu-
lar pathogenesis of malignant transformation [1]. Gene
transcription in eukaryotic cells is a highly regulated phe-
nomenon. Although the whole process has several levels
of regulation, at the top of these stands the status of chro-
matin structure which affects the ability of transcriptional
regulatory proteins and RNA polymerases to find access to
specific promoters and activate gene transcription [19].
DNA hypermethylation and histone deacetylation are crit-
ical for determining a closed chromatin structure that may
be responsible or related to the aberrant gene transcrip-Cancer Cell International 2006, 6:2 http://www.cancerci.com/content/6/1/2
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tion in the malignancies, hence its reversal using DNA
methylation inhibitors as well as histone deacetylase
inhibitors leads to antitumor effects as demonstrated in
preclinical [20] and clinical studies [21].
On these basis we wanted to analyze the antineoplastic
effect of hydralazine plus valproic acid on a panel of can-
cer cell lines from diverse origins as epigenetic alterations
are common to all tumor types investigated [22]. The
results of this study show that valproic acid has a strong
inhibitory effect in all cell lines tested and that this effect
is statistically significant increased with hydralazine in
one of these seven cell lines. However, hydralazine alone
at the concentration tested, had no growth inhibitory
properties which is not surprising. With exception of 5-
aza-2'-deoxycytidine which is a classical cytotoxic agent
with demethylating properties [23], the in vivo or in vitro
antiproliferative effects of other DNA demethylating
agents such as procainamide [24], zebularine [25], tea
polyphenol (-)-epigallocatechin-3-gallate [6] and RG108
[26] are low or absent at DNA demethylating concentra-
tions. Contrarily, valproic acid showed a strong inhibitory
effect in all cell lines tested as previously seen in a variety
of experimental systems [15]. The cytotoxicity of valproic
acid can be related to its actions on several targets such as
peroxisome proliferator-activated receptor δ (PPAR-δ),
Hierarchical clustering revealed specific patterns induced by each treatment Figure 2
Hierarchical clustering revealed specific patterns induced by each treatment. Hydralazine, valproic acid and the 
combination down-regulated a similar set of genes. On the contrary, up-regulated genes were distinctive for each treatment. 
From 1,281 differentially expressed genes, 651 were up-regulated and 630 down-regulated. The number of genes over-
expressed specific of hydralazine, valproic acid and the combination were 153, 178 and 352. Each row represents a gene, 
whereas each column corresponds to the treatment drug. The relative abundance of the gene in the tissue correlates with 
color intensity; red induced; green repressed; black no change. H: hydralazine, V: valproic acid, and HV: hydralazine and valp-
roic acid.Cancer Cell International 2006, 6:2 http://www.cancerci.com/content/6/1/2
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deregulation of β-catenin, and the transcriptional induc-
tion of the cell cycle inhibitor p21 [16,27-29], however, it
seems that its HDAC inhibitory effect is largely responsi-
ble for its cytotoxicity [30]. Interestingly, our results show
that in the cell line SW480, the combined treatment pro-
duced higher cytotoxicity than valproic acid alone as it has
been observed in other models combining a DNA
demethylating agent and a HDAC inhibitor [31,32]. The
growth inhibition of valproic acid has been associated
with a G1 or G2/M phase arrest as well as apoptosis in cer-
tain cell lines [33,34].
The data on the synergy between a DNA methylation
inhibitor and a HDAC inhibitor for gene re-expression
[35] led us to explore the effect of hydralazine plus valp-
roic acid on global gene expression. For this analysis we
chose the SW480 cancer colon cell line as it was the one
that showed higher growth inhibition with the combina-
tion of hydralazine and valproic acid (Figure 1). The
microarray analysis demonstrated that 1281 (651 up-reg-
ulated and 630 down-regulated, 2.33% from 55 000
genes) were differentially expressed at least 3-fold differ-
ent from an untreated control. Among the up-regulated
genes 153 (0.28%) were specifically induced by hydrala-
zine and 178 (0.32%) by valproic acid. However, when
cells were exposed 4 days to hydralazine and then 16
hours to valproic acid, the number rose to 352 (0.64%)
demonstrating that these epigenomic active drugs have a
synergistic effect on gene reactivation. Synergy between a
DNA methylation inhibitor 5-aza-2'-deoxycytidine and a
deacetylase inhibitor trichostatin A on gene re-expression
at a global scale is already known; like to our results it has
been shown in another system that the percentage of up-
regulated genes with 5-aza-2'-deoxycytidine was 1.9%,
and 1.1% with trichostatin A but rose to 10.4% with the
combination [36] indicating that the reversal of two epi-
genetic factors (i.e., DNA demethylation and/or histone
hyperacetylation) synergizes gene re-expression [37]. We
are currently investigating a number of cancer cell lines to
better define the patterns of gene expression induced by
these drugs; to determine whether these effects are meth-
ylation dependent or independent; and to define whether
the synergy for up-regulating genes matches the pattern of
growth inhibition observed in the cell lines.
Upon any stimuli, cells must orchestrate a number of
changes in the expression of genes as well as other
dynamic processes such as protein phosphorylation, pro-
tein trafficking, and protein-protein interactions in order
to cope with cytotoxic stress [38]. It is therefore vital for
cells to have an intact transcription regulation machinery.
On this basis we hypothesized that malignant cells
exposed to cytotoxic chemotherapeutic agents, regardless
of their intrinsic sensitivity to hydralazine, valproic acid or
the combination would have a deranged response and
Effect of cytotoxic drugs in combination with hydralazine and  valproic acid in HeLa cells Figure 3
Effect of cytotoxic drugs in combination with 
hydralazine and valproic acid in HeLa cells. HeLa cells 
were treated for 24 hours with cisplatin, adriamycin or gem-
citabine at or close to IC50 plus hydralazine and valproic acid. 
Afterwards medium was removed and fresh medium contain-
ing only hydralazine and valproic acid was added for addi-
tional 48 hours after which viability was measured. There 
was a statistically significant higher cytotoxicity of the chemo-
therapeutic agent when used in combination with hydralazine 
plus valproic acid. Viability with cisplatin was 37% and zero 
after co-treatment with hydralazine-valproic acid (p < 0.002). 
Corresponding values for adriamycin and gemcitabine alone 
or with co-treatment were 42% versus 27% (p < 0.020) and 
45% versus 37% (p < 0.012) respectively.Cancer Cell International 2006, 6:2 http://www.cancerci.com/content/6/1/2
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perhaps compromised survival if co-treated with these
two drugs that affect DNA methylation and histone
acetylation. Thus, we chose for this analysis HeLa cells
which are not inhibited by hydralazine nor showed
increased inhibition to hydralazine and valproic acid in
combination (Figure 1). The results showed that indeed,
cells exhibited increased cytotoxicity to chemotherapy
agents regardless of their mechanism of action since we
used cisplatin, a DNA-damaging agent, adriamycin a drug
targeting topoisomerase II and the antimetabolite gemcit-
abine. It is noticeable however, that the cytotoxicity was
higher for cisplatin as could be expected because loosen-
ing-up the chromatin structure by histone acetylation
increases the efficiency of anticancer drugs that target
DNA [39]. To further support our hypothesis on the
higher antitumor of cytotoxic agents when used concur-
rently with hydralazine and valproic acid led us to test the
combination plus adriamycin in a nude mice model
xenografted with HT1080 fibrosarcoma cells, that like
HeLa cells had no significantly higher growth inhibition
when treated with both hydralazine and valproic acid. The
results of higher antineoplastic effect in mice were con-
cordant with the observed in vitro for HeLa cells. Remark-
ably, while tumors receiving only adriamycin re-grew after
the last dose of adriamycin, the animals treated with
hydralazine plus valproic acid showed no tumor
regrowth. These results suggest that the antitumor efficacy
of the combination was higher and therefore no micro-
scopic residual remained or alternatively the treatment
disabled the proliferative capacity of cells. This in princi-
ple may be particularly relevant for patients who have
minimal residual disease after curative attempt by surgery,
chemotherapy, and/or radiotherapy.
Conclusion
Hydralazine and valproic acid two widely used drugs that
have DNA methyltransferase and histone deacetylase
inhibitory activities respectively have promising antineo-
plastic effects and the ability to up-regulate a number of




Cell lines MCF-7 breast adenocarcinoma, HeLa cervical
cancer, HT1080 sarcoma, KB laryngeal carcinoma, SW480
colon carcinoma, Hep-2 oral carcinoma and D54 glioma
cells were cultured at 37°C in a humidified atmosphere
containing 5% CO2 in DMEM supplemented with 10%
(v/v) fetal calf serum (Life Technologies, Inc.).
Cytotoxicity assays
Hydralazine and valproic acid alone. Cells were seeded
into 96-well microtiter Falcon plates (Becton Dickinson,
Franklin Lakes, NJ) at 1.5–2.5 × 103 cells/well in 0.1 ml of
complete medium. The next day, cells were treated for 5
days in complete medium with hydralazine at 10 µM and
valproic acid at 1 mM. Medium with drugs was changed
every other day. At day 6 cell viability was measured by
conventional MTT dye reduction assay. Briefly, 50 µl of 5
mg/ml MTT reagent in PBS were added to each well. Via-
ble cells with active mitochondria reduce the MTT to an
insoluble purple formazan precipitate that is solubilized
by the subsequent addition of 150 µl of DMSO. The for-
mazan dye was measured spectrophotometrically using
an ELISA reader. All assays were performed in triplicate.
The cytotoxic effect of each treatment was expressed as a
percentage of cell viability relative to untreated control
cells (percentage of control) and is defined as [(A570
nmtreated cells)/A570 nmnon-treated cells)] × 100.
Cytotoxicity of chemotherapy plus hydralazine and valp-
roic acid. HeLa cells were seeded into 96-well micro titer
Falcon plates (Becton Dickinson, Franklin Lakes, NJ) at
1.5–2.5 × 103 cells/well in 0.1 ml of complete medium.
The next day, cells were treated for 72 hours in complete
medium with hydralazine at 10 µM and valproic acid at 1
mM. At day four fresh medium containing hydralazine,
valproic acid plus the test drug (cisplatin at 12 µM, gem-
Antitumor effect of the combination of hydralazine and valp- roic acid plus adriamycin in a nude mice xenograft model of  fibrosarcoma Figure 4
Antitumor effect of the combination of hydralazine 
and valproic acid plus adriamycin in a nude mice 
xenograft model of fibrosarcoma. Control: solid line 
with open squares. Tumors in animal treated with adriamycin 
(dotted line with closed circles) and hydralazine-valproic acid 
and adriamycin (broken line with open triangles) had their 
tumors shrinkaged at day 21, however, in animals receiving 
hydralazine and valproic acid tumors failed to regrowth while 
in those with only adriamycin tumors increased in size 
shortly after day 21. Saline, or adriamycin injections were 
performed at days 7, 14 and 21. In the group with the three-
drug combination, hydralazine and valproic acid were admin-
istered daily from day 1 (seven days before the first injection 
of adriamycin (day 7) until sacrifice (day 35).Cancer Cell International 2006, 6:2 http://www.cancerci.com/content/6/1/2
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citabine at 2 µM and doxorubicin at 30 µM) was added for
24 hours. At day five, cell viability was assayed as above
described. The data are the mean values ± SD for n = 3.
Differences between groups were analyzed using one-way
ANOVA test. The critical level of significance was set at p
<0.05.
Gene expression
We used the Amersham (Piscataway, NJ) CodeLink sys-
tem containing 55000 genes probes. This array contains a
broad range of genes derived from publicly available,
well-annotated mRNA sequences. The CodeLink array is
unique in being capable of detecting minimal differences
in gene expression, as low as 1.3-fold with 95% confi-
dence, because of the novel three-dimensional aqueous
gel matrix, which the empirically tested 30-mer oligonu-
cleotides are deposited on [40].
Target preparation and microarray hybridization
All reagents were provided in the CodeLink expression
assay kit (Amersham, Piscataway, NJ USA), except where
noted. SW480 cells were treated with hydralazine at 10
µM for 96 hours; valproic acid for 16 hours; or both:
hydralazine for 96 hours then valproic acid was added for
additional 16 hours. Total RNA was extracted using trizol
reagent. cRNA synthesis was performed as per the manu-
facturer's instructions using 1 µg of total RNA. First-strand
cDNA was generated using Superscript II reverse tran-
scriptase and a T7 primer. Subsequently, second-strand
cDNA was produced using E. coli DNA polymerase I and
RNase H. The resultant double-stranded cDNA was puri-
fied on a QIAquick column (Qiagen, Valencia, CA) and
cRNA was generated via an in vitro transcription reaction
using T7 RNA polymerase and biotin-11-UTP (Perkin-
Elmer, Boston, MA). cRNA was purified on a RNeasy col-
umn (Qiagen), quantified by UV spectrophotometry, and
10 µg were then fragmented by heating at 94°C for 20
minutes in the presence of magnesium. The fragmented
cRNA was hybridized overnight at 37°C in hybridization
buffer to a CodeLink Whole Human Genome Bioarray in
an Innova 4080 shaking incubator (New Brunswick, Edi-
son, NJ) at 300 rpm.
Post-hybridization processing and scanning
After hybridization, the arrays were washed in 0.75× TNT
buffer at 46°C for 1 hour followed by incubation with
Cy5 Streptavidin (Amersham) at room temperature for 30
minutes in the dark. Arrays were then washed in 1× TNT
followed by a rinse in 0.05% Tween 20 in water. The slides
were then dried by centrifugation and kept in the dark
until scanning. Images were captured on ArrayWorx Scan-
ner (Applied).
Normalization and statistical analysis
Images were analyzed using CodeLink Expression Analy-
sis Software. Expression values were globally normalized
to the median expression value of the whole array spots.
Samples were normalized against the median of the con-
trol sample. To circumvent division by zero, values below
background noise were taken as 5. This step also allowed
us to manage values with CV below 10% [41]. Finally the
normalized expression data were analyzed using Cluster
2.0 [42] and Onto-tools [43].
Experiments in mice
Three groups of 6 nu/nu 6-week-old female mice (Harlan
Teklad) were injected with 6 × 106 HT1080 cells in the
flank. After 4–8 weeks, once the tumors reached a size
between 0.5 and 1 cm in diameter, groups were treated as
follows: group 1 intraperitoneal injection of 200 µl of nor-
mal saline weekly three times; group 2) intraperitoneal
injection of adriamycin at 2.2 mg/Kg weekly three times
(days 7, 14 and 21) and group 3) intraperitoneal daily
injection of both hydralazine at 5 mg/kg, and valproic
acid at a total dose of 4 mg starting 7 days before the first
application of adriamycin. Daily administration of
hydralazine and valproic acid was maintained until sacri-
fice.
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